Search

everythinglearnresearchcommunity

for

Search:↓

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Higher IL-17A levels indicate more severe alopecia areata.

Terbinafine effectively treated kerion celsi despite disrupted immune responses.

Blocking IL-17 can reduce skin inflammation in a mouse model of pityriasis rubra pilaris.

Skin bacteria, specifically Staphylococcus aureus, help in wound healing and hair growth by using IL-1β signaling. Using antibiotics on skin wounds can slow down this natural healing process.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

Mesenchymal stem cells in people with Hidradenitis Suppurativa are more inflammatory, possibly contributing to the disease.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Secukinumab effectively treated a difficult case of folliculitis decalvans.

DHT inhibition may increase spinal bone growth in ankylosing spondylitis.

A medication may help with hair growth in psoriasis, and a skin condition might be linked to a specific bacteria.

Finasteride may help treat autism by reducing inflammation and oxidative stress.

Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Two patients with psoriasis grew extra hair after using certain psoriasis medications.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

Secukinumab can cause hair loss, which may improve after stopping the medication.

Type 1/17 inflammation in psoriasis increases skin cell growth due to a molecule that could be a new treatment target.

Cholecystokinin may help reduce skin inflammation in psoriasis.

R-spondin2 may help treat hair loss, gene differences could explain baldness, a peptide's regulation is linked to psoriasis, B-defensin gene copies may affect a skin condition's risk and severity, and potential markers and targets for alopecia areata were identified.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.

Ixekizumab successfully treated a rare hair loss condition, leading to complete hair regrowth.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

Acne patients' skin, both with and without lesions, shows a strong immune response and higher antimicrobial activity.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

These specific gene polymorphisms are not linked to Alopecia Areata in Egyptians.

SH-MSCs gel can effectively treat alopecia by increasing IL-10 and decreasing TNF-α gene expression.